Table 1 Frequency distribution of comorbidities, lifestyle factors and healthcare use among two study cohorts
Characteristicb | Both cohorts N = 340,217a n (%) | Non-exposed to low-dose apirin at start of follow-up cohort N = 169,992a n (%) | New users of low-dose aspirin at start of follow-up cohort N = 170,225a n (%) |
|---|---|---|---|
Hypertension | 80,269 (23.6) | 55,228 (32.5) | 25,041 (14.7) |
Diabetes | 46,994 (13.8) | 12,365 (7.3) | 34,629 (20.3) |
COPD | 16,677 (4.9) | 7891 (4.6) | 8786 (5.2) |
IBD | 4073 (1.2) | 2061 (1.2) | 2012 (1.2) |
Depression | 69,241 (20.4) | 31,654 (18.6) | 37,587 (22.1) |
GI conditions | 71,961 (21.2) | 33,161 (19.5) | 38,800 (22.8) |
Record of prior colonoscopy, sigmoidoscopy or GI polyp | 30,150 (8.9) | 14,262 (8.4) | 15,888 (9.3) |
Smoking | |||
Non-smoker | 150,723 (44.3) | 79,726 (46.9) | 70,997 (41.7) |
Current smoker | 67,598 (19.9) | 31,157 (18.3) | 36,441 (21.4) |
Former smoker | 103,536 (30.4) | 48,552 (28.6) | 54,984 (32.3) |
Unknown | 18,360 (5.4) | 10,557 (6.2) | 7803 (4.6) |
BMI (kg/m2) | |||
15–19 | 10,581 (3.1) | 5976 (3.5) | 4605 (2.7) |
20–24 | 86,326 (25.4) | 47,714 (28.1) | 38,612 (22.7) |
25–29 | 117,293 (34.5) | 57,113 (33.6) | 60,180 (35.4) |
≥ 30 | 78,335 (23.0) | 31,460 (18.5) | 46,875 (27.5) |
Unknown | 47,682 (14.0) | 27,729 (16.3) | 19,953 (11.7) |
PCP visitsc | |||
0–1 | 11,729 (3.4) | 5842 (3.4) | 5887 (3.4) |
2–4 | 43,481 (12.8) | 21,711 (12.8) | 21,770 (12.8) |
5–9 | 98,550 (29.0) | 49,238 (29.0) | 49,312 (29.0) |
10–19 | 130,757 (38.4) | 65,353 (38.4) | 65,404 (38.4) |
≥ 20 | 55,700 (16.4) | 27,848 (16.4) | 27,852 (16.4) |